Crossmark Global Holdings’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Crossmark Global Holdings’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,070	Closed	-$62K	–	1390
2019 Q2	$62K	Buy	+10,070	New	+$48.5K	﹤0.01%	1378
2018 Q4	–	Sell	-14,740	Closed	-$92K	–	1603
2018 Q3	$92K	Buy	14,740 +130	+0.9%	+$999	﹤0.01%	1578
2018 Q2	$117K	Sell	14,610 -110	-0.7%	-$840	﹤0.01%	1569
2018 Q1	$110K	Sell	14,720 -1,890	-11%	-$12.6K	﹤0.01%	1554
2017 Q4	$99K	Sell	16,610 -24,870	-60%	-$151K	﹤0.01%	1633
2017 Q3	$305K	Buy	+41,480	New	+$263K	0.01%	1306
2016 Q3	$305K	Buy	+41,480	New	+$251K	0.01%	1306

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Crossmark Global Holdings's PGNX Position: Q3 2019 in Review

Crossmark Global Holdings sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 10,070 shares — an estimated $62K sold.

Crossmark Global Holdings first reported a position in PGNX in Q3 2016 and held it in 7 quarters. The position peaked at $305K in Q3 2017. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

Crossmark Global Holdings reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
Crossmark Global Holdings sold 10,070 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $62K.
Crossmark Global Holdings first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 7 quarters.
Crossmark Global Holdings's Progenics Pharmaceuticals Inc position peaked at $305K in Q3 2017.
135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Crossmark Global Holdings's 13F filing for Q3 2019, filed 9 Oct 2019.